Literature DB >> 19188815

Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.

V Phillips1, P Kelly, W Glenn McCluggage.   

Abstract

There are several morphologic types of ovarian carcinoma. It has been shown that p16 is overexpressed in high-grade serous carcinoma but there has been little detailed comparison of p16 expression in the common types of ovarian carcinoma. The aim of this study was to compare p16 expression in ovarian carcinomas of serous, endometrioid, clear cell, and mucinous type with a view to ascertaining whether high expression in a primary ovarian carcinoma is specific for a serous neoplasm. We included problematic cases, which are difficult to type, such as poorly differentiated and undifferentiated carcinomas and serous carcinomas with clear cells. In these problematic groups, we compared p16 expression with that of WT1, which is known to be relatively specific for a serous phenotype. Cases of ovarian high-grade serous carcinoma (n=38), endometrioid carcinoma (n=15), clear cell carcinoma (n=12), and mucinous carcinoma (n=10) were stained with p16. Cases were scored both with respect to distribution of immunoreactivity (0-5) and intensity (0-3). An immunohistochemical composite score was also calculated (0-15) by multiplying the distribution and intensity scores. Serous carcinomas typically exhibited high p16 expression; there was statistically significant higher p16 expression in serous carcinomas compared with the other morphologic types. There was high p16 and WT1 expression in most undifferentiated carcinomas and in serous carcinomas with clear cells, suggesting that these represent variants of serous carcinoma. We have demonstrated that p16 is highly expressed in high-grade serous and undifferentiated carcinomas compared with other morphologic types of ovarian carcinoma. This may be useful, in conjunction with WT1, in the classification of problematic neoplasms. p16 may be involved in the pathogenesis of high-grade ovarian serous carcinomas, possibly through inactivation of retinoblastoma protein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188815     DOI: 10.1097/PGP.0b013e318182c2d2

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  7 in total

1.  Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.

Authors:  Marián Novak; Jenny Lester; Alison M Karst; Vinita Parkash; Michelle S Hirsch; Christopher P Crum; Beth Y Karlan; Ronny Drapkin
Journal:  Gynecol Oncol       Date:  2015-07-20       Impact factor: 5.482

2.  Ovarian undifferentiated carcinoma with voluminous mesenteric presentation.

Authors:  Rosa Angélica Salcedo-Hernández; Leonardo Saúl Lino-Silva; David Cantú de León; María Delia Pérez-Montiel; Kuauhyama Luna-Ortiz
Journal:  Int J Surg Case Rep       Date:  2012-07-24

3.  Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

Authors:  Lauren Patterson Cobb; Stephanie Gaillard; Yihong Wang; Ie-Ming Shih; Angeles Alvarez Secord
Journal:  Gynecol Oncol Res Pract       Date:  2015-05-12

4.  WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis.

Authors:  Luis Felipe Sallum; Liliana Andrade; Susana Ramalho; Amanda Canato Ferracini; Rodrigo de Andrade Natal; Angelo Borsarelli Carvalho Brito; Luis Otávio Sarian; Sophie Derchain
Journal:  Oncotarget       Date:  2018-02-19

5.  The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.

Authors:  Marlene Heckl; Elisa Schmoeckel; Linda Hertlein; Miriam Rottmann; Udo Jeschke; Doris Mayr
Journal:  PLoS One       Date:  2018-02-16       Impact factor: 3.240

6.  P16 as a marker of carcinoma in effusions and peritoneal washing.

Authors:  Fabiana Pirani Carneiro; Rivadávio Fernandes Amorim; Marcos de Vasconcelos Carneiro; Tercia Maria Mendes Lousa de Castro; Leonora Maciel de Souza Vianna; Gustavo Henrique Soares Takano; Andersen Charles Daros; Isabela Peres; Selma Aparecida Souza Kuckelhaus; Andrea Barretto Motoyama
Journal:  BMC Cancer       Date:  2020-03-17       Impact factor: 4.430

7.  Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.

Authors:  Razan Sheta; Magdalena Bachvarova; Marie Plante; Marie-Claude Renaud; Alexandra Sebastianelli; Jean Gregoire; Jamilet Miranda Navarro; Ricardo Bringas Perez; Jean-Yves Masson; Dimcho Bachvarov
Journal:  J Transl Med       Date:  2020-11-19       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.